TuesdaySep 24, 2024 11:15 am

QualityStocksNewsBreaks – Mullen Automotive Inc. (NASDAQ: MULN) Shares Video Update from CEO

Mullen Automotive (NASDAQ: MULN), an emerging electric vehicle (“EV”) manufacturer, today shared a video update to shareholders provided by CEO and Chairman David Michery. In the video, Michery provides a detailed overview of the company’s recent progress, including sales and distribution expansion and financial performance. According to the update, the company’s sales activities with existing and new companies have resulted in new sales opportunities and vehicle orders received and or completed. Additionally, Mullen has secured financing to support sales growth through a $100 million preferred instrument and a $150 million fully available equity line. The update also highlighted Bollinger Motors’…

Continue Reading

TuesdaySep 24, 2024 10:00 am

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Announces Receipt of Notice of Allowance for China Patent Application Covering AVERSA(TM) Technology

Nutriband (NASDAQ: NTRB), a pharmaceutical company with a special focus on transdermal technologies, is announcing that its patent application, which protects its AVERSA(TM) abuse deterrent transdermal technology, has been allowed in China. This follows the receipt of a Notice of Allowance from the Chinese National Intellectual Property Administration (“CNIPA”) for the application entitled “Abuse and Misuse Deterrent Transdermal Systems.” The latest allowance expands the company’s international intellectual property portfolio, which now includes patents issued in 46 countries: Australia, Canada, China, Europe, Japan, Korea, Mexico, Russia, the U.S., and more. To view the full press release, visit https://ibn.fm/PeqGN About Nutriband Inc.…

Continue Reading

MondaySep 23, 2024 11:20 am

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Participation at the 24th Annual Biotech in Europe Forum

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced that CEO John Climaco will present at the 24th Annual Biotech in Europe Forum. The presentation is scheduled for Wednesday, September 25, 2024, at 1:55 p.m. CEST in Basel, Switzerland. Additionally, management will participate in in-person one-on-one meetings with qualified members of the investor community who are registered to attend the conference. To view the full press release, visit https://ibn.fm/KPZOu About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company developing…

Continue Reading

MondaySep 23, 2024 10:44 am

QualityStocksNewsBreaks – Dynasty Gold Corp.’s (TSX.V: DYG) (FSE: D5G1) (OTC: DGDCF) Initial Assay Results from 2024 Drill Program Demonstrate ‘Richness of the Gold System’ at Thundercloud

Dynasty Gold (TSX.V: DYG) (FSE: D5G1) (OTC: DGDCF), a Canadian mineral exploration company, today announced assay results for the first phase of the 2024 drill program at its Thundercloud property. The program comprises 2,198 meters. According to the announcement, drilling successfully intersected high-grade gold mineralization of 5.13 g/t Au over 18 meters from 97.5m to 115.5m, including 9.3 g/t Au over 4.5 meters and numerous 5 to 8+ g/t Au over 1.5m in drillhole TC24-02 (30 meters additional assay results are pending). In addition, drilling intersected broad zones of lower grade mineralization from 25 meters below surface with intercepts between…

Continue Reading

MondaySep 23, 2024 8:30 am

QualityStocksNewsBreaks – D-Wave Quantum Inc. (NYSE: QBTS) Announces Partnership with Staque to Accelerate Commercial Adoption of Quantum in the Middle East

D-Wave Quantum Inc. (NYSE: QBTS) (“D-Wave”), a leader in quantum computing systems, software and services, and the world’s first commercial supplier of quantum computers, has announced its partnership with Staque, a leading consulting and development practice with a focus on artificial intelligence (“AI”), blockchain and quantum computing. According to the announcement, the two companies will work to“foster collaboration and usage of quantum computing solutions for optimization and AI applications.” The companies aim to accelerate the commercial adoption of annealing quantum computing across the Middle East. “We believe organizations must embrace today’s advanced technologies such as quantum computing and AI in…

Continue Reading

MondaySep 23, 2024 8:30 am

QualityStocksNewsBreaks – AROYA Sponsors, Exhibits at Hall of Flowers Event, Open to the Public for First Time

AROYA, the leading cannabis cultivation platform, is a sponsor of the Hall of Flowers event in California and is exhibiting its state-of-the-art precision irrigation and cultivation technology at the event. The Hall of Flowers Market & Festival is slated for Sept. 21, 2024, in Sonoma, California, and is open to the public for the first time ever. According to the announcement, the company will have special product drops and offer exclusive deals for attendees, who will also be able to participate in demonstrations of the AROYA GO unit and interact with expert AROYA team members at the AROYA exhibit booth.…

Continue Reading

FridaySep 20, 2024 3:30 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs

Lexaria Bioscience Corp. (NASDAQ: LEXX), a global innovator in drug delivery platforms, looks to offer a better alternative to diabetes management and treatment through its patented DehydraTECH(TM) technology. “Lexaria has recently made strides with glucagon-like peptide-1 (‘GLP-1’) studies. It has reported positive interim results from an animal study on diabetes. This milestone best showcases the potential of its patented technology in not only addressing diabetes and obesity. Recently, the company announced the dosing completion of its human pilot study #2, GLP-1-H24-2, which sought to explore effective oral delivery of GLP-1 drugs. Some evaluated aspects included side effects, blood levels of…

Continue Reading

FridaySep 20, 2024 2:30 pm

QualityStocksNewsBreaks – Annovis Bio Inc. (NYSE: ANVS) Stands Distinct from Industry Players with Buntanetap

Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases, secured U.S. patent No. 12,042,482 covering methods for treating traumatic brain injury (“TBI”) and nerve injury with buntanetap, the company’s lead drug candidate. “Buntanetap (formerly Posiphen) targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins such as amyloid beta, tau, alpha-synuclein, and TDP43; by inhibiting their translation, the drug improves synaptic transmission, axonal transport, reduces neuroinflammation, and prevents nerve cells from dying. Unlike monoclonal antibody therapies, buntanetap is an orally available small molecule that inhibits multiple neurotoxic proteins simultaneously, making it a promising solution…

Continue Reading

FridaySep 20, 2024 12:45 pm

QualityStocksNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Inks Licensing Agreement to Use Bitrex(R) Aversive Agent for Flagship Product

Nutriband (NASDAQ: NTRB), a company engaged in the development of prescription transdermal pharmaceutical products, has signed a trademark licensing agreement for the use of Bitrex(R) brand denatonium benzoate. According to the announcement, Bitrex is the most bitter substance in the world, and Nutriband will be using it as an aversive agent in its lead product, AVERSA(TM) Fentanyl, an abuse deterrent fentanyl patch. The company’s abuse-deterrent transdermal technology includes the utilization of a proprietary aversive agent coating that uses taste aversion as a means to deter the oral abuse of and accidental exposure to transdermal opioid and stimulant patch products. According…

Continue Reading

FridaySep 20, 2024 11:40 am

QualityStocksNewsBreaks – Octane Chooses IBN as Official Media Partner for Upcoming Medical Innovation Forum 2024

Octane, an innovative organization building the SoCal of Tomorrow by connecting people, resources and capital to fuel technology growth in Southern California, has chosen IBN (“InvestorBrandNetwork”), a pioneering corporate communications firm and content distributor, as the official media partner for its next month’s Medical Innovation Forum 2024; the two-day event will be held on Oct. 8–9, 2024, in Irvine. California. The theme of this year’s event is “The Seismic Shift in Healthcare: AI & Innovation.” According to the announcement, IBN will heighten recognition and increase awareness of the Octane event among investors, journalists, consumers and the broader public of the Octane event…

Continue Reading

Market Basics

New to the micro-cap markets?Get answers to your questions about investing in Small-Cap / Micro-Cap Stocks and learn how to protect yourself.

The Basics

Newsletter Publishers

Have an up and coming newsletter and want to be included in our coverage list? Looking to get more coverage and grow subscriptions? Register for coverage.

Register

Public Companies

Are you a Small-Cap / Micro-Cap company looking for coverage? We'd love to hear from you. Fill out our quick contact form or send us a text.

Get Covered